# 日本修订《根据出口贸易管理令附表2和附表7规定的货物》(Japan Revises Goods Under Export Trade Control Order Schedules 2 and 7)

- **Source**: exportcontrol.mofcom.gov.cn
- **URL**: http://exportcontrol.mofcom.gov.cn/article/gjdt/202504/1125.html
- **Date**: 2025-04-08
- **Category**: controlled_item_change
- **Fetched**: 2026-02-08
- **confidence**: 高

## Summary
Japan's Ministry of Economy, Trade and Industry announced amendments to goods controlled under Schedules 2 and 7 of the Export Trade Control Order, adding 9 new items under Schedule 2 Item 21-3 and expanding approval requirements for exports of raw materials for narcotics or psychotropic substances, effective March 17, 2025.

## Key Details
- **Issuing Authority**: Ministry of Economy, Trade and Industry (METI)
- **Effective Date**: 2025-03-17
- **Scope**: Amendments to Export Trade Control Order Schedules 2 and 7
- **Legal Basis**: Export Trade Control Order (1949 Cabinet Order No. 378); Foreign Exchange and Foreign Trade Act

## Key Provisions
**Schedule 2 Amendments:**
- **Addition of 9 new controlled items** under Schedule 2, Item 21-3
- Specific items not detailed in summary article

**Schedule 7 Amendments:**
- Enhanced controls on exports of raw materials for narcotics or psychotropic substances
- Requires approval from Minister of Economy, Trade and Industry under Foreign Exchange and Foreign Trade Act

**Approval Requirements:**
- Exporters must obtain METI ministerial approval for newly controlled items
- Enhanced due diligence for precursor chemicals and pharmaceutical raw materials

## Supply Chain Impact Assessment
**Limited Specificity:**
- Summary article does not specify the 9 new controlled items under Schedule 2, Item 21-3
- Schedule 2 typically covers items controlled for regional security reasons or sensitive destinations
- Schedule 7 relates to items controlled under international agreements (e.g., chemical weapons, drug precursors)

**Pharmaceutical and Chemical Supply Chains:**
- **Narcotics/psychotropic precursors**: Tightened controls impact pharmaceutical manufacturers sourcing from Japan
- Legitimate pharmaceutical production requires demonstrating legal end-use
- May cause delays in supply chains for controlled substance manufacturing

**Schedule 2, Item 21-3 Context:**
- Item 21-3 historically relates to specific chemical or material controls
- Addition of 9 items suggests significant expansion in scope
- Likely targets dual-use chemicals or materials with potential illicit applications

**Compliance Implications:**
- Japanese chemical exporters: Review product portfolios against updated schedules
- International pharmaceutical companies: Verify legal compliance and licensing for precursor imports
- Enhanced documentation requirements for end-use certification

**Strategic Context:**
- Narcotics precursor controls implement international drug control obligations
- Reflects Japan's commitment to preventing illicit drug manufacturing
- Aligns with INCB (International Narcotics Control Board) recommendations

**Affected Industries:**
- Fine chemicals manufacturing
- Pharmaceutical active ingredient production
- Specialty chemical suppliers
- Research chemical suppliers

## Notes
- Article successfully fetched via WebFetch
- **Limited technical detail**: Specific 9 items under Schedule 2, Item 21-3 not listed in summary
- Full regulatory text requires consulting METI official gazette
- Controls appear to focus on drug precursors and related chemicals
- Effective date March 17, 2025 (published April 8, suggesting retroactive reporting or delayed publication)
- Companies should access complete METI notice for detailed controlled item specifications
- Confidence rated "高" based on clear regulatory information, despite limited item specificity

---
*Source: China Ministry of Commerce Export Control Information Network*
